Biotech News

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics (LRMR)Larimar TherapeuticsCompany update

BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in

Related news

Larimar Therapeutics

Intracellular Protein Delivery Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin. Nomlabofusp Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the...

Recent company news

Stock data

Close
4.18 USD
Market cap
342.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States